Vaxcyte (PCVX) earnings history
Most recent quarter
- Fiscal period
- Q4 2025
- Period end
- Dec 31, 2025
- EPS actual
- −$1.81
- EPS estimate
- −$1.53
- EPS surprise
- −18.32%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Feb 24, 2026
Vaxcyte's most recent report in the table covers Q4 2025 and was released on February 24, 2026. The company posted a loss of $1.81 per share, wider than the $1.53 loss expected, a miss of 18.32%. A year earlier, in Q4 2024, the loss was $1.02 per share. No revenue was reported for the quarter, and no revenue estimate was given.
Every quarter in the table is a loss, and losses have widened over time. The smallest was $0.41 per share in Q4 2020 and Q1 2021. Annual losses grew from $1.93 per share in 2021 to $3.44 in 2022 and $4.14 in 2023, before easing to $3.80 in 2024. The largest quarterly loss was $1.83 in Q4 2023. The table has no row for Q3 2025, so there is no full-year 2025 total; the three quarters shown add up to a loss of $4.07 per share. Vaxcyte beat the EPS estimate in 11 of the 20 quarters shown.
The table holds no results after the February 2026 report. In past years Vaxcyte reported first-quarter results between May 7 and May 11, and second-quarter results between August 6 and August 11. The next figures shown will be for Q1 2026.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2025 | Feb 24, 2026 | −$1.53 | −$1.81 | −18.32% | $0.00 | SEC |
| Q2 2025 | Aug 6, 2025 | −$1.16 | −$1.22 | −5.17% | $0.00 | SEC |
| Q1 2025 | May 7, 2025 | −$1.06 | −$1.04 | +2.02% | $0.00 | SEC |
| Q4 2024 | Feb 25, 2025 | −$1.11 | −$1.02 | +7.82% | $0.00 | SEC |
| Q3 2024 | Nov 5, 2024 | −$1.10 | −$0.83 | +24.60% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.98 | −$1.10 | −12.75% | $0.00 | SEC |
| Q1 2024 | May 8, 2024 | −$1.13 | −$0.85 | +24.70% | $0.00 | SEC |
| Q4 2023 | Feb 27, 2024 | −$1.05 | −$1.83 | −73.56% | $0.00 | SEC |
| Q3 2023 | Nov 6, 2023 | −$0.84 | −$0.91 | −8.63% | $0.00 | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.75 | −$0.70 | +6.04% | $0.00 | SEC |
| Q1 2023 | May 8, 2023 | −$0.82 | −$0.70 | +14.85% | $0.00 | SEC |
| Q4 2022 | Feb 27, 2023 | −$0.93 | −$1.03 | −10.75% | $0.00 | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.84 | −$0.93 | −11.15% | $0.00 | SEC |
| Q2 2022 | Aug 8, 2022 | −$0.69 | −$0.80 | −15.94% | $0.00 | SEC |
| Q1 2022 | May 9, 2022 | −$0.63 | −$0.68 | −8.50% | $0.00 | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.56 | −$0.55 | +1.79% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.55 | −$0.51 | +6.71% | $0.00 | SEC |
| Q2 2021 | Aug 11, 2021 | −$0.52 | −$0.46 | +12.10% | $0.00 | SEC |
| Q1 2021 | May 11, 2021 | −$0.51 | −$0.41 | +19.61% | $0.00 | SEC |
| Q4 2020 | Mar 29, 2021 | −$0.54 | −$0.41 | +24.07% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Vaxcyte (PCVX) last report earnings?
Vaxcyte last reported on Feb 24, 2026, covering fiscal Q4 2025.
Did PCVX beat earnings estimates?
No. Vaxcyte reported EPS of −$1.81 for Q4 2025 against a −$1.53 estimate — a 18.32% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.